Boston, MA, July 15, 2025 (Alloy Therapeutics) — Alloy Therapeutics, a biotechnology ecosystem company, has signed a Memorandum of Understanding with Serbia’s BIO4 Campus to foster biotech innovation. The collaboration aims to support Serbia’s national biotech goals by providing access to Alloy’s drug discovery platforms and expertise in launching biotech startups.
Anchored at the BIO4 Campus, opening in 2027 with over 1,000 PhD scientists, the initiative will empower local researchers and entrepreneurs through advanced tools, manufacturing, and business support across the R&D lifecycle. “This partnership is a strong endorsement of Serbia’s ambition to become a leader in biotechnology,” said Smiljana Krivokuća, CEO of BIO4 Campus. Alloy’s CEO, Errik Anderson, emphasized the commitment to global access to medicines. The partnership aligns with Alloy’s mission to reinvest in the scientific ecosystem, fostering cross-border innovation.
Read the full article on alloytx.com
Share this page on social